Combination therapy for visceral leishmaniasis (Q37698756)

22 August 2017

1 reference

title

Combination therapy for visceral leishmaniasis (English)

1 reference

22 August 2017

main subject

visceral leishmaniasis

1 reference

Lutgarde Lynen

1 reference

22 August 2017

Marleen Boelaert

1 reference

22 August 2017

Johan van Griensven

1 reference

22 August 2017

Manica Balasegaram

1 reference

22 August 2017

Filip Meheus

series ordinal

1 reference

22 August 2017

Jorge Alvar

series ordinal

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Lancet Infectious Diseases

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

184-194

1 reference

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

1 reference

7 January 2021

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

1 reference

7 January 2021

Chemotherapy in the treatment and control of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Paromomycin in the treatment of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Development of miltefosine for the leishmaniases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Liposomal amphotericin B for the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Visceral leishmaniasis: advances in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

A policy for leishmaniasis with respect to the prevention and control of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Drug resistance in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Treatment options for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

The relationship between leishmaniasis and AIDS: the second 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

The sensitivity of Leishmania species to aminosidine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Short-course of oral miltefosine for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

1 reference

7 January 2021

Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

The increase in risk factors for leishmaniasis worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

The economic impact of visceral leishmaniasis on households in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

The economic burden of visceral leishmaniasis for households in Nepal

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Drug policy for visceral leishmaniasis: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Clinicoepidemiological study of drug resistance in Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Comparison of regimens of treatment with sodium stibogluconate in kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Response to Interferon‐γ plus Pentavalent Antimony in Indian Visceral Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Developments in the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Modelling parasite drug resistance: lessons for management and control strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Pharmacokinetic determinants of the window of selection for antimalarial drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Artemisinin-based combination treatment of falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Antimalarial drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Artemisinin-resistant malaria in Asia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Artemisinin Resistance in Plasmodium falciparum Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Miltefosine: issues to be addressed in the future.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Development and characterization of paromomycin-resistant Leishmania donovani promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Gene amplification in amphotericin B-resistant Leishmania tarentolae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Drug resistance in Leishmania: similarities and differences to other organisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Leishmaniasis: drugs in the clinic, resistance and new developments.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Visceral leishmaniasis and HIV in Tigray, Ethiopia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Leishmania–HIV co-infection: An emerging problem in India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Tuberculosis and human immunodeficiency virus infection in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

HIV and the transmission of Leishmania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Monitoring drug resistance in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970011-6

7 January 2021

10.1016/S1473-3099(10)70011-6

Identifiers

DOI

1 reference

22 August 2017

1 reference